Fig. 3From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trialPatients with AEs by cycle in patients with best response of SD to romidepsin. Numbered bars represent the number of patients with SD treated in each cycle. Those who experienced drug-related AEs may have also experienced non-drug-related AEsBack to article page